Alzheon
Framingham, Massachusetts, United States · Biotechnology
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and
Key facts
- Headquarters
- Framingham, Massachusetts, United States
- Employees
- 31
- Industries
- Biotechnology
- Status
- Private
- Website
- alzheon.com
- Company page
Recent activity at Alzheon
- : ALZHEON
- : Alzheon, Inc. Appoints Muneer A. Satter to Board of Directors to Guide Upcoming Commercialization Efforts.
- : Alzheon, Inc. raised $100 million in Series E financing led by Alerce Medical Technology Partners to advance the development and commercialization of oral tablet ALZ-801/Valiltramiprosate for the treatment of Alzheimer’s disease.
- : ALZHEON
- : ALZHEON
- : ALZHEON
- : ALZHEON
- : Alzheon Announces Closing Of Oversubscribed $50 Million Series D Financing Round To Accelerate Completion Of Apolloe4 Phase 3 Trial And Expansion Of Product Portfolio
- : ALZHEON, INC.
- : ALZHEON, INC.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Alzheon funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $78.8M |
| Jun 2024 | Series E | $100.0M |
| Feb 2024 | Venture | $17.2M |
| Dec 2022 | Series D | $1.7M |
| Apr 2022 | Series D | $50.0M |
Leadership
- Martin Tolar, Director, Executive Officer
- Diane M.D., Director
- Noel Dunn, Director
- David Ph.D., Director
- Jordan Heller, Director
- Neil Flanzraich, Director
- Martin Ph.D., Director, Executive Officer
- Jean-Pierre Garnier, Director
- Dennis Langer, Director
- Franz Hefti, Director
Verified email and direct lines for Alzheon’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Alzheon files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Alzheon in the news
- Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London - Business Wire (Jul 06, 2026)
- Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD - Patient Care Online (Oct 28, 2025)
- Alzheon’s Oral Alzheimer’s Drug Shows Safety and Promise for APOE4/4 - Inside Precision Medicine (Oct 16, 2025)
- Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate - NeurologyLive (Aug 12, 2025)
- Oral Treatment Shows Promise in Combating Alzheimer Disease - Pharmacy Times (Sep 06, 2024)
- Alzheon Announces Peer-Reviewed Publication Showing Oral Valiltramiprosate/ALZ-801 Achieves Sustained Plasma Biomarker Reductions Linked to Better Cognitive, Functional, and Brain Atrophy Outcomes in APOE4 Carriers with Early Alzheimer’s Diseas - Business Wire (Sep 08, 2026)
- High Prevalence of CAA-Related Lesions in APOE ε4/4 Homozygotes With Early Alzheimer disease - NeurologyLive (Jul 26, 2023)
Companies similar to Alzheon
- Actinium Pharmaceuticals · Biotechnology
- Cardiff Oncology · Biotechnology
- Saniona · Biotechnology
- Diden Robotics · Biotechnology
- Qilin Zhengwei · Biotechnology
About Alzheon: questions and answers
What does Alzheon do?
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and
Where is Alzheon headquartered?
Alzheon is headquartered in Framingham, Massachusetts, United States.
How many employees does Alzheon have?
Alzheon has about 31 employees.
Has Alzheon raised funding?
Yes. Fundz has recorded 5 funding events for Alzheon. The most recent, $78.8M, was in Aug 2026.
What is the latest news on Alzheon?
On Aug 26, 2026, ALZHEON
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy